The Cigna Group v. Celgene Corporation et al.
pending- Docket:
- 1:25-cv-05237
- Court:
- S.D.N.Y.
- Filed:
- 2025-06-24
Patents:10555939
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending.
Defendant
Celgene Corporation
7 cases as defendant.
- Cases
- 7
- Active
- 3
- 4 closed
- Filed
- 2023–2025
- Top venue
- S D N Y
- 4 cases
Also appears as a plaintiff in 22 cases → View as plaintiff
Filing activity
CenterWell Pharmacy, Inc. v. Celgene Corporation
pending/consolidated- Docket:
- 1:24-cv-06924
- Court:
- S.D.N.Y.
- Filed:
- 2024-09-13
Patents:10555939
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending and consolidated with related Pomalyst antitrust actions.
New York Hotel Trades Council & Hotel Association of NYC Health Center, Inc. v. Celgene Corporation
pending- Docket:
- 1:24-cv-02230
- Court:
- S.D.N.Y.
- Filed:
- 2024-03-25
Patents:10555939
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending as of the source data.
Louisiana Health Service & Indemnity Company v. Celgene Corporation
motion to dismiss granted- Docket:
- 1:23-cv-07871
- Court:
- S.D.N.Y.
- Filed:
- 2023-09-05
Patents:10555939
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Motion to dismiss granted Mar. 2025; plaintiffs sought leave to amend.
In re Pomalyst Antitrust Litigation
on appealPatents:9993467
Antitrust litigation in S.D.N.Y. challenging Celgene's enforcement of pomalidomide patents including the '467; complaints dismissed March 2025, judgment entered for defendants March 2026, and notice of appeal to the Second Circuit filed April 2026.
The Cigna Group v. Celgene Corporation
on appeal- Docket:
- 1:25-cv-05237-ER
Patents:9993467
Antitrust action by The Cigna Group against Celgene Corp. in the Pomalyst antitrust litigation; complaints dismissed March 2025, judgment entered for defendants March 2026, and appeal to the Second Circuit filed April 2026.
In re Pomalyst (pomalidomide) Antitrust Litigation
dismissed; leave to amend soughtPutative class actions filed beginning September 2023 against Celgene, Bristol Myers Squibb, and individuals alleging antitrust, consumer-protection, and unjust-enrichment claims relating to the Pomalyst patents, including the '647 family. In March 2025 the court dismissed the complaints, and plaintiffs sought leave to amend.